36 C
Vientiane
Tuesday, May 6, 2025
spot_img
Home Blog Page 545

Cakebar Katong Unveils Singapore’s First 24/7 Self-Pickup Cake Kiosk


SINGAPORE – Media OutReach Newswire – 24 February 2025 – In a strategic move to reshape the dessert service landscape through the comprehension of local consumer needs, Cakebar Katong introduces Singapore’s first 24/7 self-pickup cake kiosk, marking a significant shift towards innovative unmanned store concepts. Setting a new standard in customer convenience, this pioneering initiative at its Katong outlet offers customers the freedom to order and collect artisan cakes and desserts around the clock from a dedicated, chilled pickup station. By integrating advanced IT and engineering solutions, Cakebar prioritises accessibility, holding its own in a competitive market increasingly dominated by online options.

Pioneering Singapore's first 24/7 self-pickup cake kiosk, Cakebar Katong revolutionises dessert accessibility for all occasions. This unmanned, fully integrated online ordering system eliminates the constraints of store hours and home refrigeration, catering to both spontaneous celebrations and planned events with unparalleled convenience and innovation.
Pioneering Singapore’s first 24/7 self-pickup cake kiosk, Cakebar Katong revolutionises dessert accessibility for all occasions. This unmanned, fully integrated online ordering system eliminates the constraints of store hours and home refrigeration, catering to both spontaneous celebrations and planned events with unparalleled convenience and innovation.

Redefining Cake Shopping with Advanced Technology

As retail trends shift towards technology-driven solutions, Cakebar emerges as a fresh contender with its automated cake kiosk, aiming to make a dent in the confectionery market. At its core, this transformative kiosk integrates advanced IT and engineering solutions with robust security measures, including long-distance remote monitoring, real-time alerts, and CCTV surveillance, along with continuous online tracking of refrigeration temperatures to ensure optimal food safety and quality.

Extending beyond the boundaries of typical cake shopping experiences, Cakebar’s technology-driven service is fully integrated with online ordering. Eliminating traditional shopping constraints, this self-pickup service offers unmatched convenience, allowing customers to skip the queues, order and pick up their cakes and desserts anytime—day or night. With a simple online ordering process, customers can choose the 24/7 pickup option at Cakebar Katong and retrieve their orders on-site in a few taps. Whether it’s a same-day pickup for orders placed before 2PM, or a next-day pickup, Cakebar ensures that every celebration or spontaneous craving is met with ease.

Enhancing Convenience with Future Service Innovations

Celebrated for its pioneering technology and creative solutions, Cakebar is set to further enhance its proprietary 24-hour service model by introducing a self-service vending machine. This future addition aims to provide not only cake pickups but also a selection of celebration essentials, such as party plates, flowers, and greeting cards—all available around the clock.

Anticipating future expansions, this Singaporean-run company is exploring ways to extend this innovative service model across its entire network of outlets, potentially offering the full customer experience 24/7 at all its locations—unmanned. This move highlights Cakebar’s ongoing efforts to marry baking with cutting-edge service innovation, anticipating new convenient ways to satisfy local customer needs in the confectionery space.



The issuer is solely responsible for the content of this announcement.

Cakebar

Cakebar is a distinguished artisan cake shop specialising in premium cakes and pastries that delight the senses with every bite. Renowned for its indulgent creations, Cakebar offers a diverse selection of desserts crafted with the finest ingredients. This online cake shop also ensures seamless home delivery across Singapore, catering to every celebration and craving, with four outlets offering either grab-and-go or dine-in options. For more information, please visit: https://cakebar.com.sg/

VVDN and Red Hat Collaborate to Deliver Cutting-Edge RAN Intelligent Controller (RIC) Solution on Red Hat OpenShift

GURUGRAM, India, Feb. 24, 2025 /PRNewswire/ — VVDN Technologies, a global provider of software, product engineering, and electronics manufacturing services and solutions, collaborates with Red Hat Inc., the world’s leading provider of open source solutions, to deploy its RAN Intelligent Controller (RIC) on Red Hat OpenShift. VVDN’s RIC is certified on Red Hat OpenShift and is set to revolutionize the performance, scalability, and security of Radio Access Networks (RAN) for global enterprises and telcos.

VVDN’s deep expertise in RIC with Red Hat OpenShift, the industry’s leading hybrid cloud application platform powered by Kubernetes, delivers unparalleled scalability, security, and real-time optimization. With the rapid adoption of 5G technologies and the growing demand for high-performance network solutions, this collaboration helps address the industry’s need for enhanced RAN management and automation.

As a certified solution on Red Hat OpenShift, VVDN’s RIC solution is designed to enhance the performance and efficiency of RAN by optimizing and automating network resources in real time. Key benefits of VVDN’s RIC solution include real-time optimization, which continuously adjusts network parameters for optimal performance and user experience, AI-driven insights that use machine learning algorithms to predict and resolve network issues before they impact users, enhanced flexibility that supports various RAN architectures and multi-vendor environments, and improved resource utilization, which maximizes efficiency and reduces operational costs.

By deploying VVDN’s RIC solution on Red Hat OpenShift, enterprises can leverage the power of Red Hat’s cloud-native capabilities containerization to deploy and manage RIC services more seamlessly. The deployment of RIC on Red Hat OpenShift offers streamlined scalability by enabling automatic scaling of RIC components to help meet demand and support high availability. It also provides enhanced flexibility with a cloud-native environment, supports integrated development using DevSecOps practices through CI/CD pipelines, and offers robust security features to protect RIC applications and data.

Puneet Agarwal, CEO, VVDN Technologies said: 

“Collaborating with Red Hat is a pivotal step for VVDN as we continue to push the boundaries of telecom innovation. This collaboration allows us to combine our RIC expertise with Red Hat’s renowned hybrid cloud application platform, Red Hat OpenShift, providing telecom operators and enterprises with a solution that meets current demands and is future-proofed for the growing complexities of 5G and beyond.”

Marshal Correia, Vice President and General Manager, Red Hat India said: 

“Red Hat is excited to collaborate with VVDN Technologies to certify their RAN Intelligent Controller on Red Hat OpenShift. Together, we aim to deliver more scalable, secure, and cloud-native solutions for modern networks. By combining RAN optimization with the capabilities of Red Hat OpenShift, this collaboration can help empower real-time optimization, AI-driven insights, and enhanced efficiency, addressing the evolving demands of enterprises and telcos in the 5G era.”

 About VVDN:

Founded in 2007, VVDN is a technology innovation company focusing primarily on Software Services, Product Engineering and Manufacturing Services.  VVDN’s India HQ is located at Gurgaon, India, and its North America HQ is located in Fremont, CA, USA. VVDN has a presence across the world with offices in US, Canada, Europe, Vietnam, South Korea, and Japan. With 11 advanced R&D Centres, VVDN is fully equipped to design, develop & test the complete hardware, mechanical & software required for a complete product or solution. VVDN’s 7 Manufacturing facilities are located at Manesar, Gurgaon, and Pollachi, Tamil Nadu, India, which includes in-house best-in-class SMT Factory, Mold & Tooling Factory, Injection Molding, Die Casting, Powder Coating, Sheet Metal, Product Assembly Factory, and Product Certifications labs. Company offers a comprehensive suite of services from Hardware to Mechanical, Embedded Software to Cloud & Apps, Testing & Validation to Automation as well as Mass Manufacturing to its global customers.

Red Hat and OpenShift are trademarks or registered trademarks of Red Hat, Inc. or its subsidiaries in the U.S. and other countries.

Arrowpoint Investment Partners Chooses SS&C for Fund Administration

WINDSOR, Conn., Feb. 24, 2025 /PRNewswire/ — SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Arrowpoint Investment Partners, Singapore’s new multi-strategy hedge fund investment firm, has selected SS&C GlobeOp to administer its flagship $1 billion multi-strategy fund. The fund currently leverages 18 portfolio managers in Hong Kong SAR and Singapore across various strategies.

“Our philosophy is to integrate multiple strategies across our teams by leveraging technology to generate consistent, high-quality, risk-adjusted returns,” said Woon Young Jeong, Chief Operating Officer of Arrowpoint. “We needed an administrator who was deeply familiar with multiple asset classes, complex fee structures, and managing reporting requirements for investors of multi-manager vehicles. SS&C’s cutting-edge technology and professional and knowledgeable support team make it an ideal partner to service our fund.”

Arrowpoint was founded by Jonathan Xiong, the former co-CEO of Millennium’s Asia operations. Rather than managing trading teams as separate entities, Arrowpoint integrates its fundamental and quant strategies across equities, fixed income and commodities to gain more precise control over performance. The firm focuses on investments in Asia.

“We are pleased to work with Arrowpoint Investment Partners as they grow their innovative fund,” said Michael Li, Managing Director, Head of SS&C GlobeOp, APAC. “As the hedge fund market evolves, multi-strategy vehicles attract much investor interest. These vehicles can be complex to manage, as multiple asset classes, fee structures and reporting requirements are involved. We look forward to working with Arrowpoint to alleviate those operational stresses so the team can focus on investing.”

Learn more about SS&C’s multi-manager fund solutions here.

About Arrowpoint Investment Partners

Arrowpoint is an investment firm building a differentiated Asia-focused, multi-strategy platform. Learn more at https://arrowpointfund.com/

About SS&C Technologies

SS&C is a global provider of services and software for the financial services and healthcare industries. Founded in 1986, SS&C is headquartered in Windsor, Connecticut, and has offices around the world. More than 22,000 financial services and healthcare organizations, from the world’s largest companies to small and mid-market firms, rely on SS&C for expertise, scale and technology.

Additional information about SS&C (Nasdaq: SSNC) is available at www.ssctech.com.

Follow SS&C on Twitter, LinkedIn and Facebook.

 

VVDN and Red Hat Collaborate to Deliver Cutting-Edge RAN Intelligent Controller (RIC) Solution on Red Hat OpenShift

GURUGRAM, India, Feb. 24, 2025 /PRNewswire/ — VVDN Technologies, a global provider of software, product engineering, and electronics manufacturing services and solutions, collaborates with Red Hat Inc., the world’s leading provider of open source solutions, to deploy its RAN Intelligent Controller (RIC) on Red Hat OpenShift. VVDN’s RIC is certified on Red Hat OpenShift and is set to revolutionize the performance, scalability, and security of Radio Access Networks (RAN) for global enterprises and telcos.

VVDN’s deep expertise in RIC with Red Hat OpenShift, the industry’s leading hybrid cloud application platform powered by Kubernetes, delivers unparalleled scalability, security, and real-time optimization. With the rapid adoption of 5G technologies and the growing demand for high-performance network solutions, this collaboration helps address the industry’s need for enhanced RAN management and automation.

As a certified solution on Red Hat OpenShift, VVDN’s RIC solution is designed to enhance the performance and efficiency of RAN by optimizing and automating network resources in real time. Key benefits of VVDN’s RIC solution include real-time optimization, which continuously adjusts network parameters for optimal performance and user experience, AI-driven insights that use machine learning algorithms to predict and resolve network issues before they impact users, enhanced flexibility that supports various RAN architectures and multi-vendor environments, and improved resource utilization, which maximizes efficiency and reduces operational costs.

By deploying VVDN’s RIC solution on Red Hat OpenShift, enterprises can leverage the power of Red Hat’s cloud-native capabilities containerization to deploy and manage RIC services more seamlessly. The deployment of RIC on Red Hat OpenShift offers streamlined scalability by enabling automatic scaling of RIC components to help meet demand and support high availability. It also provides enhanced flexibility with a cloud-native environment, supports integrated development using DevSecOps practices through CI/CD pipelines, and offers robust security features to protect RIC applications and data.

Puneet Agarwal, CEO, VVDN Technologies said: 

“Collaborating with Red Hat is a pivotal step for VVDN as we continue to push the boundaries of telecom innovation. This collaboration allows us to combine our RIC expertise with Red Hat’s renowned hybrid cloud application platform, Red Hat OpenShift, providing telecom operators and enterprises with a solution that meets current demands and is future-proofed for the growing complexities of 5G and beyond.”

Marshal Correia, Vice President and General Manager, Red Hat India said: 

“Red Hat is excited to collaborate with VVDN Technologies to certify their RAN Intelligent Controller on Red Hat OpenShift. Together, we aim to deliver more scalable, secure, and cloud-native solutions for modern networks. By combining RAN optimization with the capabilities of Red Hat OpenShift, this collaboration can help empower real-time optimization, AI-driven insights, and enhanced efficiency, addressing the evolving demands of enterprises and telcos in the 5G era.”

 About VVDN:

Founded in 2007, VVDN is a technology innovation company focusing primarily on Software Services, Product Engineering and Manufacturing Services.  VVDN’s India HQ is located at Gurgaon, India, and its North America HQ is located in Fremont, CA, USA. VVDN has a presence across the world with offices in US, Canada, Europe, Vietnam, South Korea, and Japan. With 11 advanced R&D Centres, VVDN is fully equipped to design, develop & test the complete hardware, mechanical & software required for a complete product or solution. VVDN’s 7 Manufacturing facilities are located at Manesar, Gurgaon, and Pollachi, Tamil Nadu, India, which includes in-house best-in-class SMT Factory, Mold & Tooling Factory, Injection Molding, Die Casting, Powder Coating, Sheet Metal, Product Assembly Factory, and Product Certifications labs. Company offers a comprehensive suite of services from Hardware to Mechanical, Embedded Software to Cloud & Apps, Testing & Validation to Automation as well as Mass Manufacturing to its global customers.

Red Hat and OpenShift are trademarks or registered trademarks of Red Hat, Inc. or its subsidiaries in the U.S. and other countries.

 

Logo: https://laotiantimes.com/wp-content/uploads/2025/02/vvdn_technologies_logo-1.jpg 

 

LG Display Begins Mass Production of Ultra-large Automotive Display Solutions to Revolutionize Driving Experience

SEOUL, South Korea, Feb. 24, 2025 /PRNewswire/ — LG Display, the world’s leading innovator of display technologies, announced today that it has officially begun mass production of the industry’s first 40-inch Pillar to Pillar (P2P) automotive display. The company is accelerating its push into the Software-Defined Vehicle (SDV) era by scaling up the production of premium automotive display solutions with the goal of revolutionizing the driving experience.

LG Display Begins Mass Production of Ultra-large Automotive Display Solutions
LG Display Begins Mass Production of Ultra-large Automotive Display Solutions

A P2P display is an ultra-large automotive panel that fully covers the area in front of the driver’s and front passenger’s seats.

The performance of an SDV, which is controlled by software to enhance driving convenience, requires the installation of large displays that make it easy to see a variety of information and control vehicle functions. As a result, the ultra-large P2P solution is gaining attention as a next-generation mobility display.

LG Display is ramping up its SDV strategy through the mass production of its 40-inch P2P, which offers a personalized infotainment experience for both the driver and passengers. It raises user convenience by allowing the simultaneous display of advanced infotainment functions, from a digital dashboard and navigation to climate control, movies, music, and even games – all without screen transitions.

As a result, this ultra-large display enables immediate access to varied information and easy control of vehicle functions without limitations, as opposed to previous automotive displays where navigation instructions might disappear or shrink when accessing other functions like climate control or music.

Switchable Privacy Mode (SPM) viewing angle control technology has also been applied to help the driver stay focused on the road. SPM, which LG Display was the first in the industry to commercialize, allows the front passenger to watch movies or play games on the display in front of them even as it remains invisible from the driver’s seat.

As viewing angle control technology has emerged as a key safety feature amid the trend toward larger automotive displays, LG Display’s SPM is distinguished by achieving ultra-high-definition resolution while still controlling the viewing angle.

In addition, local dimming technology has been applied for the first time, reducing heat generation and power consumption. This further increases the driving efficiency of next-generation mobility options such as electric vehicles.

The innovative design potential of future mobility is also maximized as physical buttons are minimized and various functions can be controlled via the ultra-large display.

The company’s 40-inch P2P will be installed in the Afeela, the first sedan from Japanese joint venture Sony Honda Mobility. The Afeela is a next-generation electric vehicle that combines Sony’s advanced IT and entertainment technologies with Honda’s expertise in vehicle manufacturing. The ultra-large display is expected to maximize AI-based driver assistance systems and various entertainment functions.

“Based on our industry-leading proprietary technology, outstanding product competitiveness, and stable supply capabilities, we will continue to present innovative solutions that provide differentiated customer value in the SDV era.” said Keuk-sang Kwon, Head of Auto Business Group at LG Display.

About LG Display

LG Display Co., Ltd. [NYSE: LPL, KRX: 034220] is the world’s leading innovator of display technologies, including thin-film transistor liquid crystal and OLED displays. The company manufactures display panels in a broad range of sizes and specifications primarily for use in TVs, notebook computers, desktop monitors, automobiles, and various other applications, including tablets and mobile devices. LG Display currently operates manufacturing facilities in Korea and China, and back-end assembly facilities in Korea, China, and Vietnam. The company has approximately 70,707 employees operating worldwide. For more news and information about LG Display, please visit www.lgdisplay.com.

Media Contact:
Joo Yeon Jennifer Ha, Manager, Communication Team
Email: hjy05@lgdisplay.com

HEYTEA Partners with Adyen to Brew Global Expansion

HEYTEA taps Adyen for its unified commerce technology and global acquiring capabilities to process payments in store and online

SHENZHEN, China, Feb. 24, 2025 /PRNewswire/ — Adyen, the global payments platform of choice for many of the world’s leading companies, today announced its partnership with HEYTEA, the originator of China’s “new-style tea” and creator of the iconic cheese tea (cheese cloud foam).

With a footprint of over 4,300 outlets in 300 cities worldwide, the partnership is set to be a recipe for success with HEYTEA’s ambitious global expansion, bringing its creative brews to customers across the United States, United Kingdom, Singapore, and Australia.

With its sights set on expanding into new markets, HEYTEA has chosen Adyen as its payment technology provider, utilizing Adyen’s unified commerce platform to enable the global tea chain to launch seamlessly into new overseas markets.

The integration with Adyen will also see HEYTEA unlock the benefit of its extensive global acquiring network, allowing faster, more reliable transactions in the preferred local payment methods — including powering WeChat Pay directly via HEYTEA’s app, promising a localized and more customer-friendly experience.

“Adyen’s technology allows us to seamlessly deliver on our mission to deliver a modern tea experience to customers globally,” says HEYTEA official spokesperson. “Adyen’s fast processing and support of a wide range of local payment methods, allow us to focus on delighting customers without worrying about payment complexities.”

“Adyen is proud to partner with HEYTEA as it brings its iconic ‘new-style tea’ to customers around the globe. Expanding into new markets presents both opportunities and challenges, and we’re proud that HEYTEA has trusted Adyen to power its global growth.” says Warren Hayashi, President of Asia-Pacific, Adyen.

About Adyen

Adyen (AMS: ADYEN) is the financial technology platform of choice for leading companies. By providing end-to-end payments capabilities, data-driven insights, and financial products in a single global solution, Adyen helps businesses achieve their ambitions faster. With offices around the world, Adyen works with the likes of Meta, Uber, H&M, eBay, and Microsoft. The cooperation with HEYTEA as described in this merchant update underlines Adyen’s continuous growth with current and new merchants over the years. For more information, visit adyen.com.

About HEYTEA

HEYTEA is the originator of new-style tea. Founded in 2012 in Jiangbianli, Guangdong, China, HEYTEA began with humble beginnings, blending tradition with eccentric inspiration to breathe new life into tea. Committed to using only REAL ingredients with NO colorants, HEYTEA revolutionized the tea industry by introducing the world’s first-ever Cheese Tea—a unique blend of fresh tea topped with a rich, velvety cheese cloud foam.

In 2018, HEYTEA opened its first international store in Singapore, bringing new-style tea to a larger global audience. Today, with more than 4,300 stores worldwide, HEYTEA continues to bring simple joy and a touch of Zen to more people through a good cup of tea.

NMPA Accepts NDA and Grants Priority Review Designation to Innovent’s Ipilimumab Injection, China’s First Domestic CTLA-4 Inhibitor, in Combination with Sintilimab as Neoadjuvant Treatment for Colon Cancer

SAN FRANCISCO and SUZHOU, China, Feb. 24, 2025 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that the New Drug Application (NDA) for ipilimumab injection (anti-CTLA-4 monoclonal antibody; R&D Code: IBI310) has been accepted by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) and granted Priority Review designation[1] in combination with sintilimab as neoadjuvant treatment for resectable microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer.

This is China’s first NDA for a domestic CTLA-4 inhibitor and another milestone strengthening sintilimab’s leadership position in cancer immunotherapy. Immune checkpoint blockade (ICB) therapy targeting PD-1 and CTLA-4 has transformed oncology treatment, ipilimumab with sintilimab as a neoadjuvant treatment could increase R0 resection rate, achieve pathological complete response, and relieve the majority of patients from adjuvant chemotherapy burdens. This novel treatment is also expected to reduce recurrence rate and improve long-term prognosis, anticipated to benefit MSI-H/dMMR colon cancer patients upon NDA approval.

The NDA acceptance and Priority Review designation are based on results from a randomized, controlled, multicenter, pivotal Phase 3 clinical trial (NeoShot, NCT05890742) which evaluated the safety and efficacy of ipilimumab  combined with sintilimab as neoadjuvant therapy and as compared with direct radical surgery for MSI-H/dMMR colon cancer. The primary endpoints are pathologic complete response (pCR) rate and event-free survival (EFS). Interim analysis by the Independent Data Monitoring Committee (IDMC) showed that the NeoShot trial has met its primary endpoint. Detailed results will be presented at future academic conferences or published in academic journals.

Previously, the results of a randomized controlled Phase 1b trial evaluating ipilimumab in combination with sintilimab as neoadjuvant treatment for MSI-H/dMMR colon cancer were presented orally at the 2024 American Society of Clinical Oncology (ASCO) Annual Meetingi. Based on promising Phase 1b results, the CDE has granted Breakthrough Therapy Designation (BTD) for ipilimumab.

  • As of February 4, 2024, 101 patients were enrolled and randomized to receive ipilimumab plus sintilimab (n=52) or sintilimab alone (n=49).
  • In the per-protocol population, the pCR rate in the ipilimumab-plus-sintilimab arm was significantly higher than in the sintilimab-alone arm(80.0% vs 47.7%, p=0.0007).
  • All patients in both treatment arms had R0 resection. With median follow-up of 5.65 months, no patient had disease recurrence.
  • At postoperative pathological evaluation, 3.9% of patients with ipilimumab plus sintilimab and 15.9% of patients with sintilimab alone were stage N+. The majority of patients could be relieved from adjuvant treatment according to clinical guidelines.
  • Ipilimumab -plus-sintilimab increased neither safety risk compared to sintilimab alone nor risk for subsequent surgery delay or cancellation.

The Principal Investigator of the NeoShot study, Prof. Ruihua Xu from Sun Yat-sen University Cancer Center, stated: “At present, R0 resection for certain locally advanced colon cancer patients remains a significant challenge, along with risks of extensive trauma and poor prognosis. The results of the FOxTROT study suggested that neoadjuvant chemotherapy is not effective in MSI-H/dMMR colon cancer, and the pCR rate is only around 5%ii. The NeoShot trial is the first randomized, controlled, Phase 3 clinical trial to show promising efficacy of dual checkpoint inhibition as neoadjuvant therapy in MSI-H/dMMR colon cancer. Results from the phase 1b study suggest that ipilimumab with sintilimab as short-term neoadjuvant treatment could increase R0 resection rate, achieve pathological complete response, and relieve patients from adjuvant chemotherapy burdens. This novel treatment is also expected to lower recurrence rate and improve long-term prognosis i.As this dual immunotherapy regimen has the potential to change clinical practice, we look forward to the NDA approval of this novel drug to benefit more MSI-H/dMMR colon cancer patients soon. “

Dr. Hui Zhou, Senior Vice President of Innovent, stated: “There is a huge unmet clinical need for neoadjuvant therapy of resectable MSI-H/dMMR colon cancer in China. Interim analysis showed that the NeoShot trial has met its primary endpoint. With Innovent’s highly efficient and high-quality clinical development, ipilimumab has become China’s first domestic CTLA-4 inhibitor to submit an NDA. We will actively cooperate with regulatory authorities to accelerate approval, and provide a new treatment option for patients with resectable MSI-H/dMMR colon cancer in China.”

About Ipilimumab

Ipilimumab (R&D code: IBI310) is a fully human monoclonal antibody injection independently developed by Innovent. Ipilimumab can specifically bind cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), thereby blocking CTLA-4 mediated T cell inhibition, promoting T cell activation and proliferation, improving tumor immune response, and achieving anti-tumor effects. iii

The NDA for ipilimumab in combination with sintilimab as neoadjuvant treatment for resectable microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colon cancer is under the NMPA review and has been granted Priority Review designation.

About Sintilimab

Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. Sintilimab is a type of immunoglobulin G4 monoclonal antibody, which binds to PD-1 molecules on the surface of T-cells, blocks the PD-1 / PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells.iv

In China, sintilimab has been approved and included in the updated NRDL for seven indications. The updated NRDL reimbursement scope for TYVYT® (sintilimab injection) includes:

  • For the treatment of relapsed or refractory classic Hodgkin’s lymphoma after two lines or later of systemic chemotherapy;
  • For the first-line treatment of unresectable locally advanced or metastatic non-squamous non-small cell lung cancer lacking EGFR or ALK driver gene mutations;
  • For the treatment of patients with EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer who progressed after EGFR-TKI therapy;
  • For the first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer;
  • For the first-line treatment of unresectable or metastatic hepatocellular carcinoma with no prior systematic treatment;
  • For the first-line treatment of unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma;
  • For the first-line treatment of unresectable locally advanced, recurrent or metastatic gastric or gastroesophageal junction adenocarcinoma.

Furthermore, sintilimab’s eighth indication, in combination with fruquintinib for the treatment of patients with advanced endometrial cancer with pMMR tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation, was conditional approved by the NMPA in December 2024. And the NDA for sintilimab in combination with ipilimumab as neoadjuvant treatment for resectable MSI-H/dMMR colon cancer is under the NMPA review and has been granted Priority Review designation.

In addition, two clinical studies of sintilimab have met their primary endpoints:

  • Phase 2 study of sintilimab monotherapy as second-line treatment of esophageal squamous cell carcinoma;
  • Phase 3 study of sintilimab monotherapy as second-line treatment for squamous non-small cell lung cancer with disease progression following platinum-based chemotherapy.

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 14 products in the market. It has 4 new drug applications under regulatory review, 2 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Sanofi, Incyte, Adimab, LG Chem and MD Anderson Cancer Center.

Guided by the motto, “Start with Integrity, Succeed through Action,” Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Statement:

1Innovent does not recommend the use of any unapproved drug (s)/indication (s).

2Ramucirumab (Cyramza) and Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company.

Disclaimer: Innovent does not recommend any off-label usage.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. Innovent does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of Innovent with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond Innovent’s control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Innovent’s competitive environment and political, economic, legal and social conditions.

Reference:

i.            http://abstracts.asco.org/239/AbstView_239_267235.html

ii.            Morton D, et al; FOxTROT Collaborative Group. Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. J Clin Oncol. 2023 Mar 10;41(8):1541-1552. DOI: 10.1200/JCO.22.00046.

iii.            Wolchok JD, Saenger Y. The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist. 2008;13 Suppl 4:2-9. DOI:10.1634/theoncologist.13-S4-2

iv.            Wang J, et al. Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. mAbs 2019;11(8): 1443-1451. DOI: 10.1080/19420862.2019.1654303.

 

[1] According to the Provisions for Drug Registration (SAMR Order No. 27) and Working Procedures for Priority Review and Approval of Drug Marketing Authorization (Interim) (No. 82 of 2020) implemented on July 1, and July 7, 2020, respectively, priority review and approval process is established to accelerate the development of new drugs with great clinical value and clinical urgent need. The regulatory authority will prioritize the review process and evaluation resources for NDA of the drugs that have obtained priority review qualifications, which helps accelerate the market access of these innovative drugs. Priority review designation is not an approval for marketing the drug.

 

RESPONSIBLE LEADERSHIP UNDER THE SPOTLIGHT WITH LAUNCH OF IMPACT INDEX TO HOLD BUSINESS ACCOUNTABLE

Bambuddha Group White Paper and Impact Index Insights Set the Agenda for ‘The Future of Work 2035 with Responsible Leadership’

SYDNEY, Feb. 24, 2025 /PRNewswire/ — ‘Responsible Leadership 2035’ is on the agenda at the Bambuddha Group’s Round Table with the launch of a White Paper that shines the spotlight on leadership responsibility to reimagine the future of work through flexibility, collaboration and ESG-driven leadership as calls for return to work face ongoing headwinds.

‘The Future of Work 2035 – Responsible Leadership Imperatives to Drive Growth’ White Paper sets a clear vision for workplace practice in 2035, leaving no doubt that a new era in corporate leadership is no longer a nice-to-have, but critical for the survival of business, no matter the size.

“As Australia grapples with complex challenges, the role of CEOs as responsible leaders has never been more crucial,” says Anna Sheppard, Founder and CEO of Bambuddha Group, the social enterprise that offers game-changing leadership coaching to achieve equality, fairness and kindness in workplaces across the globe. Sheppard is the author of the Responsible Leadership 2035 White Paper, published in December 2024.

Grounded by insights from the Impact Index, The Future of Work 2035 – Responsible Leadership Imperatives to Drive Growth’ roundtable explores the transformative power of leadership grounded in ESG principles. The event will see CEOs from three diverse industries across Diagnostics, Technology, and Entertainment to explore the future of Responsible Leadership and identify key focus areas for the next decade, with an emphasis on reimagining the future of work (WFH, flexibility, and collaboration), prioritising ESG and societal impact as core business strategies and understanding DEI in the now and how this becomes embedded into a long-term strategy.

ABOUT BAMBUDDHA GROUP

Bambuddha Group is an award-winning advisory and training firm, dedicated to catalysing a global shift towards responsible leadership and sustainable practices by fostering a culture of compassion, empowerment, and kindness within organisations worldwide.

By 2035, our vision is to see a world where every decision-maker leads for humanity, where organisations thrive sustainably, and where success is measured not only by financial gains but also by positive impacts on society and the environment.

Programs provide access to literacy training, industry-leading coaches, executive education, and many resources to embed sustainable change and inclusive practices for people, customers, the community, and the environment.

Bambuddha Group has won multiple awards for work in this space, including being recognised as one of the” Top 10 Leadership Development Training and Coaching Companies 2021 in APAC”, Top 50 leading light for APAC, Top 50 most impactful LinkedIn Influencers, Finalists for Telstra Best of Business Awards for Accelerating Women and now join the world stage as thought leader of the year at the Women who change the world awards in London in early April.

ABOUT BAMBUDDHA IMPACT INDEX

The Bambuddha Impact Index is grounded in transformational leadership theory, systems theory, positive psychology, corporate social responsibility (CSR), sustainable development, and social justice. It integrates inclusive leadership and community engagement models emphasising empowerment, accountability, and holistic, long-term strategies for social, environmental, and organisational change.

The framework elucidates the intricate relationship between ESG practices and profitability, fostering a deep understanding of how responsible actions drive financial outcomes. It ensures decision-makers understand the importance of sustainability initiatives by highlighting tangible outcomes, opportunities and their competitive advantage in order to guide leaders toward success.

ABOUT ANNA SHEPPARD

Anna Sheppard is a Stevie award-winning inspirational speaker and emcee and the founder and CEO of Bambuddha Group. Anna spends much of their time working as an inspirational speaker, producer, and consultant with organisations and leaders who want to understand the benefits of social responsibility through a world-leading Kindness methodology.

BAMBUDDHA ON SOCIAL